Login to Your Account



Gilead Terminates Cicletanine Trial; All Eyes Remain on Quad

By Catherine Shaffer
Staff Writer

Thursday, August 23, 2012
Gilead Sciences Inc., of Foster City, Calif., has terminated a Phase II trial of cicletanine for pulmonary arterial hypertension (PAH) due to a failure of the trial to meet its primary endpoint of improvement in exercise capacity.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription